公开(公告)号：EP3027217A1

公开(公告)日：2016-06-08

申请号：EP14742552.4

申请日：2014-07-25

申请人： University of Bradford ,  The Board of Trustees of the Leland Stanford Junior University

发明人： LOADMAN, Paul ,  FALCONER, Robert ,  GILL, Jason ,  RAO, Jianghong ,  DALDRUP-LINK, Heike E.

IPC分类号： A61K47/48 ,  A61K49/18

CPC分类号： A61K49/1866 ,  A61K31/165 ,  A61K47/60 ,  A61K47/65 ,  A61K47/6927 ,  A61K47/6929 ,  A61K49/085 ,  A61K49/186

摘要： The present inventors have harnessed the targeting of nanoparticles to tumour sites, combined with the tumour site specific elevated MMP-14 activity within one conjugate to simultaneously deliver a vascular disrupting agent (VDA) and a MRI contrast agent to a tumour site. The MMP activatable conjugate of the present invention provides both therapeutic and diagnostic functions - and is referred to as a "theranostic". The theranostic conjugate of the present invention achieves the benefits of tumour site specificity, VDA delivery and MRI contrast agent delivery in a single theranostic conjugate. Consequently, the present invention provides a cancer "theranostic" which improves therapeutic efficacy whilst simultaneously reducing dose-limiting systemic toxicities and provides a tool for rapidly and non-invasively identifying tumour location, monitoring drug delivery and pharmacodynamics.